ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 127 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $221,811 | -58.6% | 10,365 | +0.4% | 0.00% | -75.0% |
Q3 2022 | $536,000 | -5.5% | 10,327 | -13.8% | 0.01% | -20.0% |
Q2 2022 | $567,000 | -72.8% | 11,986 | -59.0% | 0.02% | -69.4% |
Q1 2022 | $2,082,000 | +3.3% | 29,254 | +8.6% | 0.05% | +44.1% |
Q4 2021 | $2,015,000 | +348.8% | 26,946 | +241.2% | 0.03% | +385.7% |
Q3 2021 | $449,000 | -80.1% | 7,897 | -84.6% | 0.01% | -83.7% |
Q2 2021 | $2,261,000 | +129.1% | 51,376 | +156.7% | 0.04% | +115.0% |
Q1 2021 | $987,000 | -46.8% | 20,011 | -54.6% | 0.02% | -61.5% |
Q4 2020 | $1,856,000 | +229.1% | 44,086 | +292.7% | 0.05% | +85.7% |
Q2 2020 | $564,000 | +169.9% | 11,227 | +93.5% | 0.03% | +366.7% |
Q2 2017 | $209,000 | -43.1% | 5,802 | -51.3% | 0.01% | -45.5% |
Q1 2017 | $367,000 | -29.2% | 11,902 | -23.1% | 0.01% | -15.4% |
Q4 2016 | $518,000 | +72.7% | 15,470 | +57.9% | 0.01% | +30.0% |
Q1 2015 | $300,000 | -34.4% | 9,800 | +9.0% | 0.01% | -37.5% |
Q4 2014 | $457,000 | -43.9% | 8,987 | -56.4% | 0.02% | -44.8% |
Q3 2014 | $815,000 | – | 20,596 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |